Form 4: Oruka SVP Agarwal Boosts Stake with Share and Option Grants

Arjun Agarwal, SVP of Finance at Oruka Therapeutics, Inc., reported the acquisition of 17,500 common shares and 70,000 employee stock options through grants.

Summary

• Arjun Agarwal, SVP of Finance at Oruka Therapeutics, Inc. (ORKA), reported transactions on January 23, 2026.
• Acquired 17,500 shares of common stock at a price of $0, likely through a grant.
• Acquired 70,000 employee stock options with an exercise price of $34.39 per share.
• Following these transactions, Agarwal beneficially owns 19,258 shares of common stock and 70,000 employee stock options.
• The 17,500 common shares vest in quarterly installments (1/16th) on March 14, June 14, September 14, and December 14 (or the immediately preceding trading day if not a trading day).
• The 70,000 stock options vest monthly (1/48th) starting from January 1, 2026.
• The reported common stock beneficial ownership includes 1,758 shares acquired under the Oruka stock purchase plan on December 8, 2025.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a key executive is generally a positive signal, indicating alignment of interests and confidence in the company's future. However, the shares were granted at $0, not purchased with cash, which slightly tempers the 'strong buy' signal.

Positives

• SVP of Finance acquiring a significant number of shares and options indicates management confidence in the company's future.
• The grants align management's interests with those of shareholders through equity ownership.

Negatives

• The shares were acquired at a $0 price, indicating a grant rather than an open market purchase, which might be seen as less of a direct cash investment by the insider.

Future Outlook

The vesting schedules for both the granted common shares and employee stock options extend into the future, indicating a long-term incentive structure for the SVP of Finance. The options have an expiration date of January 22, 2036.

Industry Context

This Form 4 filing is a standard disclosure of insider equity transactions and does not provide broader industry context. However, equity grants are a common compensation mechanism in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance.

Related Party Transactions

• Acquisition of 17,500 common shares and 70,000 employee stock options by Arjun Agarwal, SVP of Finance, from Oruka Therapeutics, Inc. as part of his compensation.

Stakeholder Impact

• Shareholders may view the insider's increased equity stake as a positive indicator of management's commitment and belief in the company's long-term prospects.
• Employees may see this as a standard executive compensation practice, potentially reinforcing confidence in leadership.

Next Steps

• Quarterly vesting of 17,500 common shares on March 14, June 14, September 14, and December 14 (or preceding trading day).
• Monthly vesting of 70,000 employee stock options (1/48th) starting January 1, 2026.

Key Dates

Recommendation

While the insider's acquisition of shares and options is a positive signal of confidence, a Form 4 filing alone provides insufficient information to issue a 'buy' or 'sell' recommendation. It is a data point that should be considered alongside comprehensive financial statements, market conditions, and company-specific news to form a complete investment thesis. The grants align executive incentives, which is generally favorable, but do not represent a direct cash investment in the open market.

Keywords

Oruka Therapeutics, ORKA, insider trading, Form 4, stock options, equity grant, Arjun Agarwal, SVP Finance, beneficial ownership